DDInter854 DDInter927
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Halothane {u} (Compound) resembles {v} (Compound) Isoflurane
Halothane {u} (Compound) binds {v} (Gene) GRIN2A
Halothane {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Halothane {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Halothane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Halothane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Halothane {u} may lead to a major life threatening interaction when taken with {v} Cisapride
Halothane {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Halothane (Compound) resembles Isoflurane (Compound)
Halothane (Compound) binds GRIN2A (Gene)
Halothane may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Halothane may lead to a major life threatening interaction when taken with Cisapride
Halothane may lead to a major life threatening interaction when taken with Cabozantinib